|Bid||3.1800 x 1100|
|Ask||3.2700 x 1000|
|Day's range||3.1400 - 3.4799|
|52-week range||1.7950 - 4.5000|
|Beta (5Y monthly)||1.42|
|PE ratio (TTM)||45.43|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The company said it learned that its products will again be covered by three Medicare Administrative Contractors.
Shares of Organogenesis Holdings (NASDAQ: ORGO) were down more than 19% as of 11 a.m. on Thursday after the company announced second-quarter earnings and withdrew annual guidance after the markets closed on Wednesday. Organogenesis is a healthcare company that makes advanced care products for the wound-healing process. The company operates in two segments, Advanced Wound Care and Surgical & Sports Medicine, and both saw declines.
ORGO earnings call for the period ending June 30, 2023.